Next Article in Journal
Strategies To Modulate Heritable Epigenetic Defects in Cellular Machinery: Lessons from Nature
Previous Article in Journal
The Liver as a Target Organ for Gene Therapy: State of the Art, Challenges, and Future Perspectives
Open AccessArticle

Biosimilars: Company Strategies to Capture Value from the Biologics Market

1
Escuela Técnica Superior de Ingeniería, Universidad de Santiago de Compostela, Rúa Lope Gómez de Marzoa s/n, Campus Vida 15782, Santiago de Compostela, Spain
2
Institute of Biotechnology, University of Cambridge, Tennis Court Rd, CB41QT, Cambridge, UK
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2012, 5(12), 1393-1408; https://doi.org/10.3390/ph5121393
Received: 8 November 2012 / Revised: 5 December 2012 / Accepted: 6 December 2012 / Published: 12 December 2012
Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to enter the biosimilars market: research and development, manufacturing, supporting activities, marketing, and lobbying. Understanding the importance of each of these capabilities will be key to maximising the value generated from the biologics patent cliff. View Full-Text
Keywords: biosimilar; patent cliff; biopharmaceutical industry; market strategy; biologics biosimilar; patent cliff; biopharmaceutical industry; market strategy; biologics
Show Figures

Figure 1

MDPI and ACS Style

Calo-Fernández, B.; Martínez-Hurtado, J.L. Biosimilars: Company Strategies to Capture Value from the Biologics Market. Pharmaceuticals 2012, 5, 1393-1408.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop